运动性急性肾损伤与新型肾功能生物标志物

大强度运动中,非创伤性急性肾损伤（acute kindey injury, AKI）经常发生,表现为血尿、蛋白尿、血红蛋白尿等。一般认为,中低程度的运动性急性肾损伤是可逆的,可完全恢复。但动物实验与人类研究均发现,严重的运动性肾损伤会导致“功能性”急性肾损伤发展为“结构性”急性肾损伤,并增加慢性肾病的风险。运动性急性肾损伤对机体的潜在健康威胁已引起国内外相关领域学者的广泛关注。血清肌酐 (serum creatinine, Scr)和尿量作为肾功能的传统经典标志物,不能特异性反映早期肾损伤,而新型肾损伤标志物可进一步明确损伤的位置及严重程度。在运动领域,利用新型生物标志物进行无创性检查,识别早期运动性急性肾损伤非常必要。本文综述了反映肾小球或肾小管损伤、细胞周期停滞和肾损伤修复的新型生物标志物,着重论述了尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL)和肾损伤分子-1（KIM-1)与肾功能的关系,以及长时间耐力运动、急性运动和高强度间歇阻力运动3种运动形式对肾功能的影响,旨在引起重视,精准识别风险,及时进行早干预。     

尿神经突起导向因子1、肾损伤分子-1、视黄醇结合蛋白水平与妊娠期高血压疾病早期肾损伤的关系研究

摘要 目的：研究尿神经突起导向因子1（Netrin-1）、肾损伤分子-1（Kim-1）、视黄醇结合蛋白（RBP）水平与妊娠期高血压疾病（HDCP）早期肾损伤的关系。方法：将我院从2017年2月～2020年2月收治的HDCP患者80例纳入研究,按照HDCP严重程度分作妊娠期高血压组22例、轻度子痫前期组32例、重度子痫前期组26例,另随机选取同期于我院接受规律孕产检以及分娩正常妊娠孕妇40例作为正常妊娠组,检测并比较各组尿Netrin-1、Kim-1、RBP水平。此外,将HDCP患者按照是否出现早期肾损伤分作肾功能损伤组42例和肾功能正常组38例,比较两组尿Netrin-1、Kim-1、RBP以及肾功能指标水平,并进行相关性分析,通过Logistic回归分析HDCP早期肾损伤的影响因素。结果：正常妊娠组、妊娠期高血压组、轻度子痫前期组、重度子痫前期组尿Netrin-1水平呈逐渐降低趋势,而尿Kim-1、RBP水平均呈逐渐升高趋势,多组数据间两两对比差异均有统计学意义（均P＜0.05）。肾功能损伤组尿Netrin-1水平低于肾功能正常组,而尿Kim-1、RBP以及血尿素氮、血肌酐、24 h尿白蛋白排出量（UAE）水平均明显高于肾功能正常组（均P＜0.05）。经Pearson相关性分析可得：HDCP早期肾损伤患者尿Netrin-1水平和血尿素氮、血肌酐、UAE均呈负相关关系,而Kim-1、RBP水平和血尿素氮、血肌酐、UAE均呈正相关关系（均P＜0.05）。经Logistic回归分析发现：尿Netrin-1是HDCP早期肾损伤的保护因素,而尿Kim-1、RBP是HDCP早期肾损伤的危险因素（均P＜0.05）。结论：随着尿Netrin-1水平的降低以及Kim-1、RBP水平的升高,HDCP早期肾损伤风险越高,检测尿Netrin-1、Kim-1、RBP水平可能有助于评估HDCP的病情严重程度和肾功能损伤。     

NGAL、KIM-1和PCT在脓毒症AKI中的标志物作用

探讨NGAL与KIM-1联合检测和PCT在重症监护病房重症患者中急性肾损伤(AKI)发生中的作用。选取2018年1月至2019年6月我院101例重症患者,其中脓毒症AKI组61例,非AKI组40例,通过分析NGAL、KIM-1和PCT在2组患者中表达水平变化情况,结合与ACR指标对比分析,评价NGAL、KIM-1和PCT在脓毒症急性肾损伤早期诊断中的价值。结果显示,所有脓毒症AKI患者均检测出明显更高的尿NGAL生物标志物水平(67.32μg/g Cr)。尿KIM-1和尿NGAL水平升高与患者ACR升高均呈正相关(p<0.001),而在脓毒症AKI患者中PCT和ACR之间观察到显著的负相关(r_s=-0.102 5, p=0.307)。通过Kruskal-Wallis检验发现,NGAL和KIM-1值显示出与脓毒症严重程度具有显著统计学意义,且直接成比例的关系(p≤0.01)。进一步检查NGAL、KIM-1和PCT标志物与病情发展的相关性表明,PCT值似乎与临床结果没有很强的相关性。尿KIM-1联合NGAL在早期检测脓毒症AKI中具有较大的预测价值;PCT是有希望的脓毒症标志物之一,但不足以提供可靠诊断依据,在肾功能下降的患者中通过PCT进行脓毒症的临床诊断需要更加谨慎。     

肾脏疾病检测的现状与应用

肾脏疾病是临床上常见而又十分严重的疾病,若不能及时发现,常引起肾衰,危及生命。随着对肾脏病的研究,肾脏疾病的检测方法也有了很大进步,建立肾损伤早期检测体系成为当务之急,目前这一体系主要包括肾小球早期损伤标志物：尿微量白蛋白(mAlb)和尿转铁蛋白(Tf);肾小管早期损伤标记物：肾小管上皮细胞的各种酶(统称尿酶)、各段肾小管脱落的抗原性物质和低分子量蛋白(LMWP);肾小球滤过率的标志物：胱氨酸蛋白酶抑制剂C(Cystatin C)。     

急性肾损伤早期诊断生物标志物研究进展

急性肾损伤(acute kidney injury,AKI)既往称为急性肾衰竭"(acute renal failure,ARF),是一种常见的致死性肾病,在一般住院病人中AKI发病率约为5％,但在重症监护病房则高达30％～50％.内科疾病引起的AKI死亡率在23％左右,但由多脏器功能不全所致者死亡率高达60％.迄今,尚无有效治疗AKI药物,一旦发生AKI,临床上只能采取支持治疗,等待肾功能的恢复.因此,早期诊断及早期治疗是防治AKI的最佳策略.生物标记物是近年来研究早期诊断AKI的热点和趋势,研究发现包括NGAL,KIM-1,IL-18,NHE3等多种标记物是早期预测AKI强力指标,本文就急性肾损伤早期诊断生物标志物研究进展进行综述.     

重症急性肾损伤患者经连续性肾脏替代治疗后肾功能恢复的影响因素

目的：通过研究重症急性肾损伤患者经连续性’肾脏替代治疗后肾功能恢复的影响因素,为重症急性肾损伤患者的诊治及预后提供科学依据。方法：选取2009年7月至2013年10月本院住院且采用CRRT治疗的284例重症急性肾损伤患者,记录患者的一般资料、APACHEII评分、血液生化指标、伴随症状及肾功能预后情况,将预后情况和各影响因素进行Logistic回归分析得出影响。肾功能恢复的影响因素。结果：284例重症急性肾损伤患者中,肾功能恢复有89例（31．33％）;肾功能恢复组的年龄、衰竭器官数、APACHEⅡ评分、动脉血二氧化碳分压、合并慢性肾脏病率及合并严重基础疾病率均低于肾功能未恢复组,而平均动脉压和血小板计数高于肾功能未恢复组（P〈0．05）,两组间合并机械通气率和合并少／无尿率无统计学差异（P〉0．05）;衰竭器官数、APAC—HEⅡ评分、合并严重基础疾病及AKl分期为CRRT治疗重症急性肾损伤患者肾功能恢复的危险因素。结论：CRRT治疗重症急性肾损伤的主要危险因素为衰竭器官数、APACHEⅡ评分、合并严重基础疾病及AKl分期。在临床治疗中,应正确评估病情,早期及时采取CRRT治疗,以提高生存率,促进肾脏功能恢复。     

血液中肾损伤分子-1(KIM-1)和血清肌酐(SCr)对AKI的生物标志物作用

为了探讨血液中肾损伤分子-1 (KIM-1)和血清肌酐(SCr)的表达对外科术后急性肾损伤(AKI)的早期诊断价值,本研究选取医院内2018年3月至2019年3月进行外科手术的患者48例,分为AKI组患者即实验组12例,非AKI组患者即对照组36例,收集所有患者手术后0、3 h、6 h、9 h、12 h、24 h、48 h和72 h的血液样本,检测各个时间点血液中KIM-1和血清肌酐SCr水平,将血液中KIM-1与血清肌酐SCr水平进行相关统计学分析,绘制受试者工作特征曲线(ROC),探究并对比血液中KIM-1和血清肌酐的表达对外科手术后患者发生AKI的早期诊断价值。本研究数据显示,AKI组患者在手术后(3 h, 6 h, 9 h, 12 h)血液中KIM-1水平都高于0 h基准值,并且在6 h达到最大值;与此同时,AKI组患者手术后(0, 3 h, 6 h, 9 h)血液中KIM-1水平明显高于非AKI组患者。AKI组患者手术后血液中KIM-1 (0, 3 h, 6 h, 9 h)水平和手术后24 h的血清肌酐SCr水平呈正相关。本研究表明,3~9 h血液中KIM-1水平升高对患者外科手术后AKI的发生具备较高的诊断价值,血液中KIM-1可以作为早期诊断患者外科手术后发生AKI的一项生物标志物,且血清肌酐SCr的观测效率明显低于血液中KIM-1,可作为辅助诊疗手段。     

创伤患者急性肾功能损伤诊断与治疗

目的：探讨患者创伤后发生急性肾损伤的患者发病率、临床特点以及发病危险因素,以便有效预防和及早治疗。方法：回顾性分析我院重症监护室2004年1月至2010年12月收治的创伤患者相关临床资料,分析创伤后急性肾损伤的发病率以及发病危险因素。结果：共有106例患者纳入我们的研究,其中47例患者创伤后并发急性肾损伤。在发生急性肾损伤患者中,平均年龄为31±19岁,84．6％为男性;其中25例为脓毒血症引起,18例是因为低血压导致急性肾功能损伤。所有患者中,24例患者出现了少尿的症状,19例患者进行了透析治疗。腹部外伤[（OR）-3．66,P-0．027]和应用呋塞来[（OR=4．10,P=0.026）]是发生急性肾损伤的危险因素。结论：急性肾损伤时创伤后的严重并发症之一,死亡率高。只有找到创伤后发生急性肾损伤的危险因素,才能有效预防和及早治疗。     

急性肾损伤生物标志物的研究进展

正急性肾损伤(acute kidney injury,AKI)是常见的临床综合征,特别是在重症监护病房等单元。临床上血肌酐增高的程度和尿量变化是目前AKI的诊断指标,但肌酐不是反映肾功能变化的可靠指标,临床局限性较大,因此通过基础研究和临床研究发现理想的生物标志物势在必行,这对AKI的诊断、治疗、判断预后及预防极其重要。近年来的研究发     

创伤患者急性肾功能损伤诊断与治疗

目的:探讨患者创伤后发生急性肾损伤的患者发病率、临床特点以及发病危险因素,以便有效预防和及早治疗。方法:回顾性分析我院重症监护室2004年1月至2010年12月收治的创伤患者相关临床资料,分析创伤后急性肾损伤的发病率以及发病危险因素。结果:共有106例患者纳入我们的研究,其中47例患者创伤后并发急性肾损伤。在发生急性肾损伤患者中,平均年龄为31±19岁,84.6%为男性;其中25例为脓毒血症引起,18例是因为低血压导致急性肾功能损伤。所有患者中,24例患者出现了少尿的症状,19例患者进行了透析治疗。腹部外伤[(OR)=3.66,P=0.027]和应用呋塞米[(OR=4.10,P=0.026)]是发生急性肾损伤的危险因素。结论:急性肾损伤时创伤后的严重并发症之一,死亡率高。只有找到创伤后发生急性肾损伤的危险因素,才能有效预防和及早治疗。     

Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested case–control study

The aim of this nested case–control study was to assess the combined use of urinary kidney injury molecule (KIM)-1 and interleukin (IL)-18 for acute kidney injury (AKI) after cardiopulmonary bypass surgery (CPB). From a cohort of 122 subjects who underwent CPB, serial urinary KIM-1 and IL-18 concentrations were determined in 30 AKI and 92 non-AKI patients. An increased level of urinary KIM-1 was associated with the occurrence of AKI, whereas an increased level of IL-18 was related to progressive AKI. The combination of these two biomarkers facilitates the early diagnosis and assessment of the likely progression of AKI after CPB.     

心脏术后急性肾损伤的研究进展

急性肾损伤（Acute Kidney Injury,AKI）是心脏术后较常见且较严重的并发症,明显增加患者的住院费用,并且增加手术死亡率。研究发现术前肾功能不全、糖尿病、及外周血管疾病等是术后AKI的危险因素。最新的研究发现一些新的生物学标准物可以为我们早期诊断心脏术后AKI的发生的提供帮助。而一旦出现AKI,选择适当药物治疗和肾脏替代治疗,可以保护肾功能,改善AKI患者的预后。     

IGFBP7 regulates sepsis-induced acute kidney injury through ERK1/2 signaling

IGFBP7 as an early biomarker has been used to identify patients at risk of developing acute kidney injury (AKI). Nevertheless, its role in AKI remains obscure. The aim of our study is to determine the role and mechanism of IGFBP7 in lipopolysaccharide (LPS)-induced HK-2 cells in vitro and on sepsis-induced AKI by cecal ligation and puncture (CLP) in vivo. Here, we identified that IGFBP7 expression was increased in patients with AKI and HK-2 cells with LPS (1, 2, and 5 μg/mL) induction. HK-2 cells with LPS induction showed cell cycle arrest at G1-G0 phases and cell apoptosis and activated ERK1/2 parallel with the changes in the proteins belonging to the ERK1/2 pathway, including Cyclin D1, P21, Bax, and Bcl-2, which were inhibited by the IGFBP7 knockdown. Moreover, IGFBP7 overexpression significantly induced cell cycle arrest at G1-G0 phases and cell apoptosis of HK-2 cells, which were inhibited by PD98509, an ERK1/2 signaling inhibitor. IGFBP7 knockdown effectively alleviated the severity of the renal injury, evidenced by decreases in the urinary levels of creatinine, blood urea nitrogen, and albumin, cell apoptosis, and activation of ERK1/2 signaling in CLP mice. Taken together, our findings indicate that IGFBP7 regulates sepsis-induced AKI through ERK1/2 signaling.     

Potential advantages of acute kidney injury management by mesenchymal stem cells

Mesenchymal stem cells are currently considered as a promising tool for therapeutic application in acute kidney injury (AKI) management. AKI is characterized by acute tubular injury with rapid loss of renal function. After AKI, inflammation, oxidative stress and excessive deposition of extracellular matrix are the molecular events that ultimately cause the end-stage renal disease. Despite numerous improvement of supportive therapy, the mortality and morbidity among patients remain high. Therefore, exploring novel therapeutic options to treat AKI is mandatory. Numerous evidence in animal models has demonstrated the capability of mesenchymal stem cells (MSCs) to restore kidney function after induced kidney injury. After infusion, MSCs engraft in the injured tissue and release soluble factors and microvesicles that promote cell survival and tissue repairing. Indeed, the main mechanism of action of MSCs in tissue regeneration is the paracrine/endocrine secretion of bioactive molecules. MSCs can be isolated from several tissues, including bone marrow, adipose tissue, and blood cord; pre-treatment procedures to improve MSCs homing and their paracrine function have been also described. This review will focus on the application of cell therapy in AKI and it will summarize preclinical studies in animal models and clinical trials currently ongoing about the use of mesenchymal stem cells after AKI.     

Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass

The purpose of this study was to compare the performance of six candidate urinary biomarkers, kidney injury molecule (KIM)-1, N-acetyl-β-D-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL)-18, cystatin C and α-1 microglobulin, measured 2?h following cardiopulmonary bypass (CPB) for the early detection of acute kidney injury (AKI) in a prospective cohort of patients undergoing cardiac surgery. A total of 103 subjects were enrolled; AKI developed in 13%. Urinary KIM-1 achieved the highest area under-the-receiver-operator-characteristic curve (AUC 0.78, 95% confidence interval 0.64–0.91), followed by IL-18 and NAG. Only urinary KIM-1 remained independently associated with AKI after adjustment for a preoperative AKI prediction score (Cleveland Clinic Foundation score; p?=?0.02), or CPB perfusion time (p?=?0.006). In this small pilot cohort, KIM-1 performed best as an early biomarker for AKI. Larger studies are needed to explore further the role of biomarkers for early detection of AKI following cardiac surgery.     

Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion

Macrophage migration inhibitory factor (MIF) is pleiotropic cytokine that has multiple effects in many inflammatory and immune diseases. This study reveals a potential role of MIF in acute kidney injury (AKI) in patients and in kidney ischemic reperfusion injury (IRI) mouse model in MIF wild‐type (WT) and MIF knockout (KO) mice. Clinically, plasma and urinary MIF levels were largely elevated at the onset of AKI, declined to normal levels when AKI was resolved and correlated tightly with serum creatinine independent of disease causes. Experimentally, MIF levels in plasma and urine were rapidly elevated after IRI‐AKI and associated with the elevation of serum creatinine and the severity of tubular necrosis, which were suppressed in MIF KO mice. It was possible that MIF may mediate AKI via CD74/TLR4‐NF‐κB signalling as mice lacking MIF were protected from AKI by largely suppressing CD74/TLR‐4‐NF‐κB associated renal inflammation, including the expression of MCP‐1, TNF‐α, IL‐1β, IL‐6, iNOS, CXCL15(IL‐8 in human) and infiltration of macrophages, neutrophil, and T cells. In conclusion, our study suggests that MIF may be pathogenic in AKI and levels of plasma and urinary MIF may correlate with the progression and regression of AKI.     

Cystatin C,a novel urinary biomarker for sensitive detection of acute kidney injury during haemorrhagic fever with renal syndrome

To explore the value of cystatin C for evaluating acute kidney injury (AKI) in haemorrhagic fever with renal syndrome (HFRS), the concentrations of cystatin C in serum and urine samples from HFRS patients were determined. The serum and urinary cystatin C concentrations significantly increased in HFRS patients compared with normal controls (p?<?0.001). In the acute phase of HFRS, urinary cystatin C increased to higher levels than serum creatinine, especially in severe or critical cases in the oliguric stage. Furthermore, higher levels of urinary cystatin C in the acute phase positively correlated with increased severity of the subsequent kidney injury. In conclusion, urinary cystatin C is a more sensitive clinical marker for AKI in HFRS, which may enable us to initiate treatment measures as early as possible.